BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Koronis Pharmaceuticals, Inc. Announces Issuance of U.S. Patent for KP-1461 Therapeutic in Development for Treatment of HIV


7/23/2007 8:44:53 AM

SEATTLE, July 23 /PRNewswire/ -- Koronis Pharmaceuticals, Inc. today announced the issuance of U.S. Patent No. 7,244,732 that discloses the composition of KP-1461 -- the Company's lead antiviral therapeutic currently in a Phase 2 trial for the treatment of human immunodeficiency virus (HIV) infection.

The issued patent, titled "Prodrugs of Heteroaryl Compounds", covers the use and composition of KP-1461, an oral, small molecule antiviral therapeutic that works by Viral Decay AccelerationTM (VDA). VDA moves the virus to the point of collapse by increasing its naturally high rate of mutation. Drugs based on VDA, such as KP-1461, cause random errors throughout the viral genome at a rate that becomes unsustainable by the viral population and eventually drives it to the point of extinction. In vitro experiments have demonstrated the VDA mechanism, and scientists anticipate that similar findings will be noted in clinical trials of HIV-infected patients.

"It is significant to receive this first patent for a viral decay acceleration molecule, KP-1461, which is truly an innovative antiviral therapeutic approach unlike anything on the market or in development," said Donald Elmer, Chairman and interim chief executive officer of Koronis. "This extends our strong patent portfolio for VDA that now includes a total of seven issued U.S. patents."

About KP-1461

KP-1461 is currently in a Phase 2a clinical trial designed to evaluate the safety, efficacy and tolerability when KP-1461 is administered as monotherapy in treatment-experienced patients. The study is enrolling individuals who harbor significant resistance to conventional antiretroviral therapies and is conducted at academic and community-based clinical research centers in the United States. Preliminary results from the Phase 1b safety and pharmacology trial in therapy-experienced HIV-infected patients have demonstrated KP-1461 to be safe and well tolerated.

About Koronis

Koronis Pharmaceuticals, Inc. is a privately held biotechnology company developing anti-viral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). In addition to the Company's lead product candidate, KP-1461 for AIDS/HIV, the Company has products in development for the treatment of hepatitis C and RSV. For more information on Koronis, please visit http://www.koronispharma.com.

Koronis Pharmaceuticals, Inc.

CONTACT: Julie Rathbun of Rathbun Communications, Inc., +1-206-769-9219,julie@rathbuncomm.com, for Koronis Pharmaceuticals, Inc.



Read at BioSpace.com

   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES